Cedars-Sinai Medical Center
- Type
- Teaching hospital
- Where
- West Hollywood, CA
- Medicare CCN
- 050625
- Received
- $21,345,357 in 1,283 records, 2022 ($5,501,286 general, $15,844,070 research)
- Source
- CMS Open Payments search ↗
On this site
- Business registration: Cedars-Sinai Medical Center Fuzzy (name and state)
- Business registration: CEDARS-SINAI MEDICAL CENTER Fuzzy (name and state)
- Nonprofit contractor: CEDARS-SINAI MEDICAL CENTER Fuzzy (name and state)
- Plan sponsor: CEDARS-SINAI MEDICAL CENTER Fuzzy (name and state)
- Federal award recipient: CEDARS-SINAI MEDICAL CENTER Fuzzy (name and state)
- Lobbying client: CEDARS-SINAI MEDICAL CENTER Fuzzy (name and state)
- Lobbying client: CEDARS-SINAI MEDICAL CENTER Fuzzy (name and state)
- Lobbying client: CEDARS-SINAI MEDICAL CENTER Fuzzy (name and state)
- Lobbying client: CEDARS-SINAI MEDICAL CENTER Fuzzy (name and state)
- Lobbying registrant: CEDARS-SINAI MEDICAL CENTER Fuzzy (name and state)
- Patent assignee: CEDARS-SINAI MEDICAL CENTER Fuzzy (name and state)
- Trademark owner: Cedars-Sinai Medical Center Fuzzy (name and state)
By year
| Program year | Kind | Records | Amount |
|---|---|---|---|
| 2022 | General payment | 314 | $5,501,286 |
| 2022 | Research payment | 969 | $15,844,070 |
By company
By nature of payment
| Nature | Records | Amount |
|---|---|---|
| Research payment | 969 | $15,844,070 |
| Royalty or License | 9 | $3,264,154 |
| Grant | 75 | $1,180,142 |
| Compensation for services other than consulting, including serving as faculty or as a speaker at a v | 12 | $401,770 |
| Education | 62 | $180,108 |
| Space rental or facility fees (teaching hospital only) | 76 | $166,610 |
| Gift | 4 | $121,499 |
| Long term medical supply or device loan | 30 | $115,688 |
| Charitable Contribution | 31 | $49,726 |
| Debt forgiveness | 14 | $20,235 |
| Consulting Fee | 1 | $1,350 |
Records
| Date | Company | Amount | Nature | Form | Product | Study | Year |
|---|---|---|---|---|---|---|---|
| 2022-12-31 | Merck Sharp & Dohme LLC | $417,204 | Research payment | In-kind items and services | KEYTRUDA Biological, ONCOLOGY | An Open-label, Randomized Phase 3 Study to Evaluate Efficacy and Safety of Pembrolizumab MK-3475 in Combination with Bel | 2022 |
| 2022-12-31 | Merck Sharp & Dohme LLC | $283,030 | Research payment | In-kind items and services | KEYTRUDA Biological, ONCOLOGY | Phase Ib,II Trial of anti-PD-1 immunotherapy and Stereotactic Radiation in Patients with Recurrent Glioblastoma | 2022 |
| 2022-12-31 | Merck Sharp & Dohme LLC | $189,005 | Research payment | In-kind items and services | KEYTRUDA Biological, ONCOLOGY | An Open-label, Multicenter, Phase 2 Study to Evaluate the Efficacy and Safety of Pembrolizumab Plus Lenvatinib in Combin | 2022 |
| 2022-12-31 | Merck Sharp & Dohme LLC | $143,913 | Research payment | In-kind items and services | NOXAFIL Drug, INFECTIOUS DISEASE | A SINGLE-CENTER OPEN-LABEL PROSPECTIVE PILOT STUDY OF POSACONAZOLE IN GENETICALLY-DEFINED PATIENTS WITH ACTIVE CROHN'S D | 2022 |
| 2022-12-31 | Merck Sharp & Dohme LLC | $100,962 | Research payment | Cash or cash equivalent | KEYTRUDA Biological, ONCOLOGY | A Randomized, Double-Blind, Phase III Study of Pembrolizumab versus Placebo in Combination with Neoadjuvant Chemotherapy | 2022 |
| 2022-12-31 | Merck Sharp & Dohme LLC | $80,162 | Research payment | In-kind items and services | KEYTRUDA Biological, ONCOLOGY | A Clinical Trial of Pembrolizumab MK-3475 Evaluating Predictive Biomarkers in Subjects with Advanced Solid Tumors KEYNOT | 2022 |
| 2022-12-31 | Merck Sharp & Dohme LLC | $60,451 | Research payment | In-kind items and services | KEYTRUDA Biological, ONCOLOGY | A Randomized, Double-Blind, Phase III Study of Pembrolizumab versus Placebo in Combination with Neoadjuvant Chemotherapy | 2022 |
| 2022-12-31 | Merck Sharp & Dohme LLC | $22,125 | Research payment | In-kind items and services | WELIREG Drug, ONCOLOGY | An Open-label, Multicenter, Phase 2 Study to Evaluate the Efficacy and Safety of Pembrolizumab Plus Lenvatinib in Combin | 2022 |
| 2022-12-31 | Merck Sharp & Dohme LLC | $17,648 | Research payment | In-kind items and services | WELIREG Drug, ONCOLOGY | An Open-label, Randomized, Phase 3 Study of MK-6482 in Combination with Lenvatinib MK-7902 vs Cabozantinib for Treatment | 2022 |
| 2022-12-31 | Intuitive Surgical, Inc. | $16,840 | Long term medical supply or device loan | In-kind items and services | DAVINCI XI Device, SURGERY | 2022 | |
| 2022-12-31 | Merck Sharp & Dohme LLC | $15,749 | Research payment | Cash or cash equivalent | KEYTRUDA Biological, ONCOLOGY | A Phase II Clinical Trial to Study the Efficacy and Safety of Pembrolizumab MK-3475 andPembrolizumab in Combination with | 2022 |
| 2022-12-31 | Merck Sharp & Dohme LLC | $15,338 | Research payment | In-kind items and services | LENVIMA Drug, ONCOLOGY | A Multicenter, Open-label Phase 2 Study of Lenvatinib E7080,MK-7902 Plus Pembrolizumab MK-3475 in Previously Treated Sub | 2022 |
| 2022-12-31 | Merck Sharp & Dohme LLC | $14,461 | Research payment | Cash or cash equivalent | KEYTRUDA Biological, ONCOLOGY | A Randomized, Double-Blind, Phase 3 Study of Pemetrexed Platinum Chemotherapy with or without Pembrolizumab MK-3475 in | 2022 |
| 2022-12-31 | AngioDynamics, Inc. | $13,000 | Long term medical supply or device loan | In-kind items and services | Solero Device, Oncology | 2022 | |
| 2022-12-31 | Merck Sharp & Dohme LLC | $12,106 | Research payment | In-kind items and services | WELIREG Drug, ONCOLOGY | An Open-label, Randomized Phase 3 Study to Evaluate Efficacy and Safety of Pembrolizumab MK-3475 in Combination with Bel | 2022 |
| 2022-12-31 | KARL STORZ Endoscopy-America | $10,367 | Education | In-kind items and services | n.a. Device, LAPAROSCOPY | 2022 | |
| 2022-12-31 | Merck Sharp & Dohme LLC | $9,962 | Research payment | In-kind items and services | KEYTRUDA Biological, ONCOLOGY | A Phase II Clinical Trial to Study the Efficacy and Safety of Pembrolizumab MK-3475 andPembrolizumab in Combination with | 2022 |
| 2022-12-31 | Merck Sharp & Dohme LLC | $9,899 | Research payment | In-kind items and services | KEYTRUDA Biological, ONCOLOGY | A Randomized, Double-Blind, Phase III Study of Pembrolizumab versus Placebo in Combination with Neoadjuvant Chemotherapy | 2022 |
| 2022-12-31 | Merck Sharp & Dohme LLC | $9,562 | Research payment | In-kind items and services | WELIREG Drug, ONCOLOGY | A Phase 2 Trial of PT2977 in Combination with Cabozantinib in Patients with Advanced Clear Cell Renal Cell Carcinoma | 2022 |
| 2022-12-31 | Merck Sharp & Dohme LLC | $8,741 | Research payment | In-kind items and services | WELIREG Drug, ONCOLOGY | A Phase 2 Study to Evaluate the Efficacy and Safety of Belzutifan MK-6482, formerly PT2977 Monotherapy in Participants w | 2022 |
| 2022-12-31 | Brahms GmbH | $6,000 | Research payment | In-kind items and services | BRAHMS KRYPTOR compact PLUS (instrument) Device, Kryptor instrument | Identification and Validation of a Cut-off for the Ratio of Soluble Fms-like Tyrosine Kinase-1 to Placental Growth Facto | 2022 |
| 2022-12-31 | Merck Sharp & Dohme LLC | $5,332 | Research payment | In-kind items and services | LENVIMA Drug, ONCOLOGY | A Multicenter, Open-label Phase 2 Study of Lenvatinib E7080,MK-7902 Plus Pembrolizumab MK-3475 in Previously Treated Sub | 2022 |
| 2022-12-31 | Merck Sharp & Dohme LLC | $5,030 | Research payment | In-kind items and services | WELIREG Drug, ONCOLOGY | An Open-label, Multicenter, Phase 2 Study to Evaluate the Efficacy and Safety of Pembrolizumab Plus Lenvatinib in Combin | 2022 |
| 2022-12-31 | Intuitive Surgical, Inc. | $5,000 | Education | In-kind items and services | DAVINCI XI Device, SURGERY | 2022 | |
| 2022-12-31 | Intuitive Surgical, Inc. | $5,000 | Education | In-kind items and services | DAVINCI XI Device, SURGERY | 2022 | |
| 2022-12-31 | Merck Sharp & Dohme LLC | $4,785 | Research payment | In-kind items and services | WELIREG Drug, ONCOLOGY | A Phase 2 Study to Evaluate the Efficacy and Safety of Belzutifan MK-6482, formerly PT2977 Monotherapy in Participants w | 2022 |
| 2022-12-31 | Merck Sharp & Dohme LLC | $4,758 | Research payment | In-kind items and services | WELIREG Drug, ONCOLOGY | An Open-label, Randomized, Phase 3 Study of MK-6482 in Combination with Lenvatinib MK-7902 vs Cabozantinib for Treatment | 2022 |
| 2022-12-31 | Merck Sharp & Dohme LLC | $4,541 | Research payment | In-kind items and services | KEYTRUDA Biological, ONCOLOGY | A Clinical Trial of Pembrolizumab MK-3475 Evaluating Predictive Biomarkers in Subjects with Advanced Solid Tumors KEYNOT | 2022 |
| 2022-12-31 | KARL STORZ Endoscopy-America | $4,249 | Education | In-kind items and services | 2022 | ||
| 2022-12-31 | Merck Sharp & Dohme LLC | $4,023 | Research payment | In-kind items and services | WELIREG Drug, ONCOLOGY | An Open-label, Randomized Phase 3 Study to Evaluate Efficacy and Safety of Pembrolizumab MK-3475 in Combination with Bel | 2022 |
| 2022-12-31 | Merck Sharp & Dohme LLC | $3,953 | Research payment | In-kind items and services | KEYTRUDA Biological, ONCOLOGY | A Phase III, Randomized, Double-blind Study to Evaluate Pembrolizumab plus Chemotherapy vs Placebo plus Chemotherapy as | 2022 |
| 2022-12-31 | KARL STORZ Endoscopy-America | $3,931 | Education | In-kind items and services | 2022 | ||
| 2022-12-31 | Merck Sharp & Dohme LLC | $3,659 | Research payment | In-kind items and services | WELIREG Drug, ONCOLOGY | A Phase 2 Trial of PT2977 in Combination with Cabozantinib in Patients with Advanced Clear Cell Renal Cell Carcinoma | 2022 |
| 2022-12-31 | COLOPLAST CORP | $3,602 | Debt forgiveness | Cash or cash equivalent | Titan Device, Men's Health | 2022 | |
| 2022-12-31 | Merck Sharp & Dohme LLC | $3,242 | Research payment | In-kind items and services | WELIREG Drug, ONCOLOGY | A Phase 2 Study to Evaluate the Efficacy and Safety of Belzutifan MK-6482, formerly PT2977 Monotherapy in Participants w | 2022 |
| 2022-12-31 | KARL STORZ Endoscopy-America | $3,010 | Debt forgiveness | In-kind items and services | HOPKINS Device, LAPAROSCOPY | 2022 | |
| 2022-12-31 | KARL STORZ Endoscopy-America | $2,856 | Education | In-kind items and services | n.a. Device, LAPAROSCOPY | 2022 | |
| 2022-12-31 | Intuitive Surgical, Inc. | $2,720 | Long term medical supply or device loan | In-kind items and services | DAVINCI XI Device, SURGERY | 2022 | |
| 2022-12-31 | Intuitive Surgical, Inc. | $2,720 | Long term medical supply or device loan | In-kind items and services | DAVINCI XI Device, SURGERY | 2022 | |
| 2022-12-31 | KARL STORZ Endoscopy-America | $2,194 | Education | In-kind items and services | HOPKINS Device, LAPAROSCOPY | 2022 | |
| 2022-12-31 | KARL STORZ Endoscopy-America | $2,194 | Education | In-kind items and services | HOPKINS Device, LAPAROSCOPY | 2022 | |
| 2022-12-31 | KARL STORZ Endoscopy-America | $2,162 | Education | In-kind items and services | 2022 | ||
| 2022-12-31 | KARL STORZ Endoscopy-America | $2,117 | Education | In-kind items and services | n.a. Device, LAPAROSCOPY | 2022 | |
| 2022-12-31 | Stryker Corporation | $2,068 | Long term medical supply or device loan | In-kind items and services | SPY-PHI SYSTEM Device, ENDOSCOPY | 2022 | |
| 2022-12-31 | COLOPLAST CORP | $1,980 | Debt forgiveness | Cash or cash equivalent | Titan Device, Men's Health | 2022 | |
| 2022-12-31 | KARL STORZ Endoscopy-America | $1,923 | Education | In-kind items and services | 2022 | ||
| 2022-12-31 | KARL STORZ Endoscopy-America | $1,836 | Education | In-kind items and services | n.a. Device, LAPAROSCOPY | 2022 | |
| 2022-12-31 | AstraZeneca Pharmaceuticals LP | $1,765 | Research payment | In-kind items and services | LYNPARZA Drug, Oncology | \";A Phase III, Randomised, Double Blind, Placebo Controlled, Multicentre Study of Olaparib Maintenance Monotherapy in P | 2022 |
| 2022-12-31 | Merck Sharp & Dohme LLC | $1,728 | Research payment | In-kind items and services | KEYTRUDA Biological, ONCOLOGY | A Phase II Clinical Trial to Study the Efficacy and Safety of Pembrolizumab MK-3475 andPembrolizumab in Combination with | 2022 |
| 2022-12-31 | AstraZeneca Pharmaceuticals LP | $1,520 | Research payment | In-kind items and services | TAGRISSO Drug, Oncology | To assess the efficacy and safety of AZD9291 versus Placebo in patients with Epidermal Growth Factor Receptor Mutation P | 2022 |
| 2022-12-31 | Merck Sharp & Dohme LLC | $1,450 | Research payment | In-kind items and services | KEYTRUDA Biological, ONCOLOGY | A Randomized, Double-Blind, Phase 3 Study of Pemetrexed Platinum Chemotherapy with or without Pembrolizumab MK-3475 in | 2022 |
| 2022-12-31 | KARL STORZ Endoscopy-America | $1,308 | Education | In-kind items and services | HOPKINS Device, LAPAROSCOPY | 2022 | |
| 2022-12-31 | AstraZeneca Pharmaceuticals LP | $1,290 | Research payment | In-kind items and services | A Biomarker-Directed Phase 2 Platform Study in Patients with Advanced Non-Small Cell Lung Cancer whose Disease has Progr | 2022 | |
| 2022-12-31 | KARL STORZ Endoscopy-America | $1,203 | Education | In-kind items and services | HOPKINS Device, LAPAROSCOPY | 2022 | |
| 2022-12-31 | Merck Sharp & Dohme LLC | $1,079 | Research payment | In-kind items and services | LENVIMA Drug, ONCOLOGY | An Open-label, Randomized, Phase 3 Study of MK-6482 in Combination with Lenvatinib MK-7902 vs Cabozantinib for Treatment | 2022 |
| 2022-12-31 | Stryker Corporation | $1,015 | Long term medical supply or device loan | In-kind items and services | 2022 | ||
| 2022-12-31 | Merck Sharp & Dohme LLC | $988 | Research payment | In-kind items and services | KEYTRUDA Biological, ONCOLOGY | A Randomized, Double-Blind, Phase 3 Study of Pemetrexed Platinum Chemotherapy with or without Pembrolizumab MK-3475 in | 2022 |
| 2022-12-31 | ABBVIE INC. | $981 | Research payment | In-kind items and services | Study To Assess Adverse Events and Change in Disease Activity Of 24-hour Continuous Subcutaneous Infusion Of ABBV-951 In | 2022 | |
| 2022-12-31 | KARL STORZ Endoscopy-America | $971 | Education | In-kind items and services | HOPKINS Device, LAPAROSCOPY | 2022 | |
| 2022-12-31 | AstraZeneca UK Limited | $961 | Research payment | In-kind items and services | An open-label fixed sequence, study to assess the effect of repeated doses of capivasertib on the pharmacokinetics of or | 2022 | |
| 2022-12-31 | KARL STORZ Endoscopy-America | $898 | Education | In-kind items and services | HOPKINS Device, LAPAROSCOPY | 2022 | |
| 2022-12-31 | KARL STORZ Endoscopy-America | $898 | Education | In-kind items and services | HOPKINS Device, LAPAROSCOPY | 2022 | |
| 2022-12-31 | Siemens Medical Solutions USA, Inc. | $750 | Research payment | In-kind items and services | CSMC2019MRIPR785Xie | 2022 | |
| 2022-12-31 | Merck Sharp & Dohme LLC | $722 | Research payment | In-kind items and services | KEYTRUDA Biological, ONCOLOGY | A Randomized, Double-Blind, Phase III Study of Pembrolizumab versus Placebo in Combination with Neoadjuvant Chemotherapy | 2022 |
| 2022-12-31 | Merck Sharp & Dohme LLC | $680 | Research payment | In-kind items and services | KEYTRUDA Biological, ONCOLOGY | A Phase III, Randomized, Double-blind Study to Evaluate Pembrolizumab plus Chemotherapy vs Placebo plus Chemotherapy as | 2022 |
| 2022-12-31 | KARL STORZ Endoscopy-America | $612 | Education | In-kind items and services | n.a. Device, LAPAROSCOPY | 2022 | |
| 2022-12-31 | Stryker Corporation | $573 | Long term medical supply or device loan | In-kind items and services | LOVESEAT SLEEPER Device, FURNITURE | 2022 | |
| 2022-12-31 | KARL STORZ Endoscopy-America | $555 | Debt forgiveness | In-kind items and services | 2022 | ||
| 2022-12-31 | Merck Sharp & Dohme LLC | $532 | Research payment | Cash or cash equivalent | KEYTRUDA Biological, ONCOLOGY | A Phase III, Randomized, Double-blind Study to Evaluate Pembrolizumab plus Chemotherapy vs Placebo plus Chemotherapy as | 2022 |
| 2022-12-31 | Brahms GmbH | $519 | Research payment | In-kind items and services | BRAHMS PlGF plus KRYPTOR kits and BRAHMS sFlt-1 KRYPTOR kits Device, prenatal screening | Identification and Validation of a Cut-off for the Ratio of Soluble Fms-like Tyrosine Kinase-1 to Placental Growth Facto | 2022 |
| 2022-12-31 | KARL STORZ Endoscopy-America | $446 | Education | In-kind items and services | 2022 | ||
| 2022-12-31 | Stryker Corporation | $430 | Long term medical supply or device loan | In-kind items and services | SYMMETRY II LOWBACK CHAIR W/ ARMS Device, FURNITURE | 2022 | |
| 2022-12-31 | KARL STORZ Endoscopy-America | $427 | Education | In-kind items and services | n.a. Device, LAPAROSCOPY | 2022 | |
| 2022-12-31 | KARL STORZ Endoscopy-America | $414 | Education | In-kind items and services | HOPKINS Device, LAPAROSCOPY | 2022 | |
| 2022-12-31 | Merck Sharp & Dohme LLC | $412 | Research payment | In-kind items and services | LYNPARZA Biological, ONCOLOGY | A Phase 2 Study of Olaparib Monotherapy in Participants with Previously Treated, Homologous Recombination Repair Mutatio | 2022 |
| 2022-12-31 | KARL STORZ Endoscopy-America | $389 | Education | In-kind items and services | 2022 | ||
| 2022-12-31 | KARL STORZ Endoscopy-America | $375 | Education | In-kind items and services | n.a. Device, LAPAROSCOPY | 2022 | |
| 2022-12-31 | KARL STORZ Endoscopy-America | $348 | Education | In-kind items and services | HOPKINS Device, LAPAROSCOPY | 2022 | |
| 2022-12-31 | Stryker Corporation | $340 | Debt forgiveness | Cash or cash equivalent | 2022 | ||
| 2022-12-31 | KARL STORZ Endoscopy-America | $292 | Education | In-kind items and services | n.a. Device, LAPAROSCOPY | 2022 | |
| 2022-12-31 | KARL STORZ Endoscopy-America | $277 | Education | In-kind items and services | HOPKINS Device, LAPAROSCOPY | 2022 | |
| 2022-12-31 | KARL STORZ Endoscopy-America | $274 | Education | In-kind items and services | HOPKINS Device, LAPAROSCOPY | 2022 | |
| 2022-12-31 | KARL STORZ Endoscopy-America | $228 | Debt forgiveness | In-kind items and services | HOPKINS Device, LAPAROSCOPY | 2022 | |
| 2022-12-31 | KARL STORZ Endoscopy-America | $208 | Education | In-kind items and services | n.a. Device, LAPAROSCOPY | 2022 | |
| 2022-12-31 | Medline Industries LP | $159 | Debt forgiveness | Cash or cash equivalent | 2022 | ||
| 2022-12-31 | Merck Sharp & Dohme LLC | $149 | Research payment | In-kind items and services | KEYTRUDA Biological, ONCOLOGY | A Randomized, Phase III Trial to Evaluate the Efficacy and Safety of MK-3475 as Adjuvant Therapy for Triple Receptor-Neg | 2022 |
| 2022-12-31 | KARL STORZ Endoscopy-America | $125 | Education | In-kind items and services | HOPKINS Device, LAPAROSCOPY | 2022 | |
| 2022-12-31 | KARL STORZ Endoscopy-America | $125 | Education | In-kind items and services | HOPKINS Device, LAPAROSCOPY | 2022 | |
| 2022-12-31 | KARL STORZ Endoscopy-America | $116 | Education | In-kind items and services | n.a. Device, LAPAROSCOPY | 2022 | |
| 2022-12-31 | KARL STORZ Endoscopy-America | $101 | Education | In-kind items and services | n.a. Device, LAPAROSCOPY | 2022 | |
| 2022-12-31 | Brahms GmbH | $55 | Research payment | In-kind items and services | BRAHMS KRYPTOR BUFFER and Solution 1, 4 Device, prenatal screening | Identification and Validation of a Cut-off for the Ratio of Soluble Fms-like Tyrosine Kinase-1 to Placental Growth Facto | 2022 |
| 2022-12-31 | KARL STORZ Endoscopy-America | $53 | Education | In-kind items and services | HOPKINS Device, LAPAROSCOPY | 2022 | |
| 2022-12-31 | KARL STORZ Endoscopy-America | $47 | Education | In-kind items and services | 2022 | ||
| 2022-12-31 | KARL STORZ Endoscopy-America | $45 | Education | In-kind items and services | HOPKINS Device, LAPAROSCOPY | 2022 | |
| 2022-12-31 | Stryker Corporation | $31 | Debt forgiveness | Cash or cash equivalent | 2022 | ||
| 2022-12-31 | KARL STORZ Endoscopy-America | $22 | Education | In-kind items and services | HOPKINS Device, LAPAROSCOPY | 2022 | |
| 2022-12-31 | KARL STORZ Endoscopy-America | $21 | Education | In-kind items and services | n.a. Device, LAPAROSCOPY | 2022 | |
| 2022-12-31 | AstraZeneca Pharmaceuticals LP | $18 | Research payment | In-kind items and services | TAGRISSO Drug, Oncology | A Study of Osimertinib With or Without Chemotherapy as 1st Line Treatment in Patients With Mutated Epidermal Growth Fact | 2022 |
| 2022-12-31 | KARL STORZ Endoscopy-America | $16 | Long term medical supply or device loan | In-kind items and services | n.a. Device, CLEANING STERILIZATION CARE | 2022 | |
| 2022-12-31 | AstraZeneca Pharmaceuticals LP | $15 | Research payment | In-kind items and services | IMFINZI Biological, Oncology | This is a randomized open label multi center global Phase III study to assess the efficacy and safety of durvalumab plus | 2022 |
| 2022-12-31 | KARL STORZ Endoscopy-America | $12 | Education | In-kind items and services | n.a. Device, LAPAROSCOPY | 2022 | |
| 2022-12-31 | KARL STORZ Endoscopy-America | $10 | Education | In-kind items and services | n.a. Device, LAPAROSCOPY | 2022 | |
| 2022-12-31 | KARL STORZ Endoscopy-America | $8 | Education | In-kind items and services | n.a. Device, LAPAROSCOPY | 2022 | |
| 2022-12-31 | KARL STORZ Endoscopy-America | $7 | Education | In-kind items and services | 2022 | ||
| 2022-12-30 | Celgene Corporation | $17,550 | Research payment | Cash or cash equivalent | Expanded Access Protocol (EAP) for Patients Receiving Idecabtagene Vicleucel (ide-cel) that is Non-conforming for Commer | 2022 | |
| 2022-12-30 | Janssen Research & Development, LLC | $285 | Research payment | Cash or cash equivalent | A Phase 1 First inhuman Open Label Dose Escalation Study of JNJ61186372 a Human Bispecific EGFR and cMet Antibody in Sub | 2022 | |
| 2022-12-29 | PFIZER INC. | $9,250 | Research payment | Cash or cash equivalent | XTANDI Drug, ONCOLOGY | A RANDOMIZED PHASE II TRIAL OF SALVAGE RADIOTHERAPY WITH STANDARD VS ENHANCED ANDROGEN DEPRIVATION THERAPY WITH ENZALUTA | 2022 |
| 2022-12-28 | Boston Scientific Corporation | $22,500 | Grant | Cash or cash equivalent | GENERAL - THERAPIES Device, THERAPIES | 2022 | |
| 2022-12-28 | Alkermes, Inc. | $21,570 | Research payment | Cash or cash equivalent | A Phase 2, Open-label, Multicenter, Cohort Study of Nemvaleukin Alfa (ALKS 4230) Monotherapy Administered Subcutaneously | 2022 | |
| 2022-12-28 | Alkermes, Inc. | $3,327 | Research payment | Cash or cash equivalent | A Phase 2, Open-label, Multicenter, Cohort Study of Nemvaleukin Alfa (ALKS 4230) Monotherapy Administered Subcutaneously | 2022 | |
| 2022-12-28 | Boston Scientific Corporation | $1,500 | Grant | Cash or cash equivalent | GENERAL - THERAPIES Device, THERAPIES | 2022 | |
| 2022-12-28 | Alkermes, Inc. | $557 | Research payment | Cash or cash equivalent | A Phase 2, Open-label, Multicenter, Cohort Study of Nemvaleukin Alfa (ALKS 4230) Monotherapy Administered Subcutaneously | 2022 | |
| 2022-12-28 | Alkermes, Inc. | $557 | Research payment | Cash or cash equivalent | A Phase 2, Open-label, Multicenter, Cohort Study of Nemvaleukin Alfa (ALKS 4230) Monotherapy Administered Subcutaneously | 2022 | |
| 2022-12-28 | Alkermes, Inc. | $520 | Research payment | Cash or cash equivalent | A Phase 2, Open-label, Multicenter, Cohort Study of Nemvaleukin Alfa (ALKS 4230) Monotherapy Administered Subcutaneously | 2022 | |
| 2022-12-28 | Alkermes, Inc. | $390 | Research payment | Cash or cash equivalent | A Phase 2, Open-label, Multicenter, Cohort Study of Nemvaleukin Alfa (ALKS 4230) Monotherapy Administered Subcutaneously | 2022 | |
| 2022-12-28 | Alkermes, Inc. | $260 | Research payment | Cash or cash equivalent | A Phase 2, Open-label, Multicenter, Cohort Study of Nemvaleukin Alfa (ALKS 4230) Monotherapy Administered Subcutaneously | 2022 | |
| 2022-12-28 | Alkermes, Inc. | $260 | Research payment | Cash or cash equivalent | A Phase 2, Open-label, Multicenter, Cohort Study of Nemvaleukin Alfa (ALKS 4230) Monotherapy Administered Subcutaneously | 2022 | |
| 2022-12-28 | Alkermes, Inc. | $234 | Research payment | Cash or cash equivalent | A Phase 2, Open-label, Multicenter, Cohort Study of Nemvaleukin Alfa (ALKS 4230) Monotherapy Administered Subcutaneously | 2022 | |
| 2022-12-26 | Boston Scientific Corporation | $21,160 | Research payment | Cash or cash equivalent | CLINICAL TRIAL PRODUCT Device, IC | ACURATE IDE | 2022 |
| 2022-12-23 | Roche Products Limited | $2,131 | Research payment | Cash or cash equivalent | OCREVUS Biological, Immunology | OBSERVATIONAL STUDY OF OCRELIZUMAB TREATED MULTIPLE SCLEROSIS PATIENTS US COMMITMENT | 2022 |
| 2022-12-22 | Cook Medical LLC | $27,000 | Charitable Contribution | In-kind items and services | COOK Device, HEMOSTASIS | 2022 | |
| 2022-12-22 | Intercept Pharmaceuticals, Inc. | $24,710 | Research payment | Cash or cash equivalent | OCALIVA Drug, Hepatology / Gastroenterology | Study of OCA in Combination With BZF Evaluating Efficacy, Safety, and Tolerability in Patients With PBC | 2022 |
| 2022-12-22 | Cook Medical LLC | $5,150 | Charitable Contribution | In-kind items and services | COOK Device, HEMOSTASIS | 2022 | |
| 2022-12-22 | Cook Medical LLC | $1,120 | Charitable Contribution | In-kind items and services | ECHOTIP ULTRA Device, ENDOSCOPIC ULTRASOUND | 2022 | |
| 2022-12-22 | Cook Medical LLC | $1,050 | Charitable Contribution | In-kind items and services | COTTON-LEUNG Device, MISC. - NON-BILIARY | 2022 | |
| 2022-12-22 | Cook Medical LLC | $1,020 | Charitable Contribution | In-kind items and services | COTTON-LEUNG Device, BILIARY | 2022 | |
| 2022-12-22 | Cook Medical LLC | $912 | Charitable Contribution | In-kind items and services | ECHOTIP PROCORE Device, ENDOSCOPIC ULTRASOUND | 2022 | |
| 2022-12-22 | Cook Medical LLC | $906 | Charitable Contribution | In-kind items and services | FUSION Device, BILIARY | 2022 | |
| 2022-12-22 | Cook Medical LLC | $876 | Charitable Contribution | In-kind items and services | MEMORY BASKET Device, BILIARY | 2022 | |
| 2022-12-22 | Cook Medical LLC | $854 | Charitable Contribution | In-kind items and services | FUSION Device, BILIARY | 2022 | |
| 2022-12-22 | Cook Medical LLC | $766 | Charitable Contribution | In-kind items and services | SOEHENDRA Device, BILIARY | 2022 | |
| 2022-12-22 | Cook Medical LLC | $630 | Charitable Contribution | In-kind items and services | ECHOTIP Device, ENDOSCOPIC ULTRASOUND | 2022 | |
| 2022-12-22 | Cook Medical LLC | $510 | Charitable Contribution | In-kind items and services | THE WEB Device, BILIARY | 2022 | |
| 2022-12-22 | Cook Medical LLC | $502 | Charitable Contribution | In-kind items and services | FUSION QUATTRO Device, BILIARY | 2022 | |
| 2022-12-22 | Cook Medical LLC | $502 | Charitable Contribution | In-kind items and services | ACROBAT Device, BILIARY | 2022 | |
| 2022-12-22 | Cook Medical LLC | $436 | Charitable Contribution | In-kind items and services | COTTON-LEUNG Device, MISC. - NON-BILIARY | 2022 | |
| 2022-12-22 | Cook Medical LLC | $430 | Charitable Contribution | In-kind items and services | ECHOTIP PROCORE Device, ENDOSCOPIC ULTRASOUND | 2022 | |
| 2022-12-22 | Cook Medical LLC | $428 | Charitable Contribution | In-kind items and services | TRACER METRO Device, BILIARY | 2022 | |
| 2022-12-22 | Cook Medical LLC | $420 | Charitable Contribution | In-kind items and services | SOEHENDRA Device, BILIARY | 2022 | |
| 2022-12-22 | Cook Medical LLC | $416 | Charitable Contribution | In-kind items and services | COOK Device, BILIARY | 2022 | |
| 2022-12-22 | Cook Medical LLC | $408 | Charitable Contribution | In-kind items and services | ROADRUNNER Device, BILIARY | 2022 | |
| 2022-12-22 | Cook Medical LLC | $404 | Charitable Contribution | In-kind items and services | GLO-TIP Device, BILIARY | 2022 | |
| 2022-12-22 | Cook Medical LLC | $368 | Charitable Contribution | In-kind items and services | FUSION Device, BILIARY | 2022 | |
| 2022-12-22 | Cook Medical LLC | $352 | Charitable Contribution | In-kind items and services | SOEHENDRA Device, BILIARY | 2022 | |
| 2022-12-22 | Cook Medical LLC | $340 | Charitable Contribution | In-kind items and services | FUSION Device, BILIARY | 2022 | |
| 2022-12-22 | Cook Medical LLC | $325 | Charitable Contribution | In-kind items and services | ECHOTIP Device, ENDOSCOPIC ULTRASOUND | 2022 | |
| 2022-12-22 | Cook Medical LLC | $279 | Charitable Contribution | In-kind items and services | UTS Device, BILIARY | 2022 | |
| 2022-12-22 | Cook Medical LLC | $268 | Charitable Contribution | In-kind items and services | FUSION OASIS Device, BILIARY | 2022 | |
| 2022-12-22 | Cook Medical LLC | $216 | Charitable Contribution | In-kind items and services | SOEHENDRA Device, BILIARY | 2022 | |
| 2022-12-22 | Cook Medical LLC | $172 | Charitable Contribution | In-kind items and services | GLO-TIP Device, BILIARY | 2022 | |
| 2022-12-22 | Cook Medical LLC | $166 | Charitable Contribution | In-kind items and services | HUIBREGTSE KATON Device, BILIARY | 2022 | |
| 2022-12-22 | SEAGEN INC. | $99 | Research payment | Cash or cash equivalent | Phase 1b/2 study of SGN-LIV1A in combination with pembrolizumab in patients with locally advanced or metastatic triple-n | 2022 | |
| 2022-12-22 | SEAGEN INC. | $99 | Research payment | Cash or cash equivalent | Phase 1b/2 study of SGN-LIV1A in combination with pembrolizumab in patients with locally advanced or metastatic triple-n | 2022 | |
| 2022-12-22 | SEAGEN INC. | $99 | Research payment | Cash or cash equivalent | Phase 1b/2 study of SGN-LIV1A in combination with pembrolizumab in patients with locally advanced or metastatic triple-n | 2022 | |
| 2022-12-22 | SEAGEN INC. | $99 | Research payment | Cash or cash equivalent | Phase 1b/2 study of SGN-LIV1A in combination with pembrolizumab in patients with locally advanced or metastatic triple-n | 2022 | |
| 2022-12-22 | SEAGEN INC. | $99 | Research payment | Cash or cash equivalent | Phase 1b/2 study of SGN-LIV1A in combination with pembrolizumab in patients with locally advanced or metastatic triple-n | 2022 | |
| 2022-12-22 | SEAGEN INC. | $99 | Research payment | Cash or cash equivalent | Phase 1b/2 study of SGN-LIV1A in combination with pembrolizumab in patients with locally advanced or metastatic triple-n | 2022 | |
| 2022-12-22 | SEAGEN INC. | $99 | Research payment | Cash or cash equivalent | Phase 1b/2 study of SGN-LIV1A in combination with pembrolizumab in patients with locally advanced or metastatic triple-n | 2022 | |
| 2022-12-21 | PFIZER INC. | $16,608 | Research payment | Cash or cash equivalent | A PHASE 1 DOSE ESCALATION AND EXPANSION STUDY TO EVALUATE SAFETY TOLERABILITY PHARMACOKINETIC PHARMACODYNAMIC AND ANTITU | 2022 | |
| 2022-12-21 | Novartis Pharmaceuticals Corporation | $13,382 | Grant | Cash or cash equivalent | 2022 | ||
| 2022-12-21 | Grifols Therapeutics LLC | $780 | Research payment | Cash or cash equivalent | Albutein Biological, Critical Care Medicine | Effects of Plasma Exchange With Human Serum Albumin 5 PE-A 5 on Short-term Survival in Subjects With Acute-On-Chronic Li | 2022 |
| 2022-12-21 | Apellis Pharmaceuticals, Inc. | $345 | Research payment | Cash or cash equivalent | MERIDIAN: A Study to Evaluate the Efficacy and Safety of Pegcetacoplan in Adults With Amyotrophic Lateral Sclerosis (ALS | 2022 | |
| 2022-12-21 | Grifols Therapeutics LLC | $168 | Research payment | Cash or cash equivalent | Albutein Biological, Critical Care Medicine | Effects of Plasma Exchange With Human Serum Albumin 5 PE-A 5 on Short-term Survival in Subjects With Acute-On-Chronic Li | 2022 |
| 2022-12-20 | Otsuka Pharmaceutical Development & Commercialization, Inc. | $22,500 | Research payment | Cash or cash equivalent | A PHASE 3, MULTICENTER, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY TO ASSESS THE EFFICACY, SAFETY, AND TOLERABIL | 2022 | |
| 2022-12-20 | Roche Products Limited | $3,247 | Research payment | Cash or cash equivalent | TECENTRIQ Biological, BioOncology | A PHASE III MULTICENTER RANDOMIZED OPEN LABEL STUDY COMPARING ATEZOLIZUMAB ANTI PD L1 ANTIBODY | 2022 |
| 2022-12-20 | E.R. Squibb & Sons, L.L.C. | $2,500 | Space rental or facility fees (teaching hospital only) | Cash or cash equivalent | OPDIVO Biological, Oncology | 2022 | |
| 2022-12-20 | Kite Pharma, Inc. | $1,500 | Space rental or facility fees (teaching hospital only) | Cash or cash equivalent | Yescarta Drug, CELLT | 2022 | |
| 2022-12-19 | Merck Sharp & Dohme LLC | $194,077 | Research payment | Cash or cash equivalent | WELIREG Drug, ONCOLOGY | A Phase 2 Study to Evaluate the Efficacy and Safety of Belzutifan MK-6482, formerly PT2977 Monotherapy in Participants w | 2022 |
| 2022-12-19 | Boston Scientific Corporation | $120,911 | Research payment | Cash or cash equivalent | CLINICAL TRIAL PRODUCT Device, CLINICAL TRIAL PRODUCT | ACURATE IDE | 2022 |
| 2022-12-19 | PFIZER INC. | $88,502 | Research payment | Cash or cash equivalent | DAURISMO Drug, ONCOLOGY | AN OPENLABEL PHASE 1B STUDY OF PF04449913 GLASDEGIB IN COMBINATION WITH AZACITIDINE IN PATIENTS WITH PREVIOUSLY UNTREATE | 2022 |
| 2022-12-19 | Medtronic, Inc. | $37,279 | Research payment | Cash or cash equivalent | COREVALVE EVOLUT R Device, Transcatheter Valve Systems | CoreValve SURTAVI | 2022 |
| 2022-12-19 | Genentech, Inc. | $15,236 | Research payment | Cash or cash equivalent | Drug | A PHASE 2B EFFICACY SAFETY TRIAL OF PRASINEZUMAB IN PATIENTS WITH EARLY PARKINSON S DISEASE | 2022 |
| 2022-12-19 | Celgene Corporation | $5,000 | Grant | Cash or cash equivalent | 2022 | ||
| 2022-12-19 | Boston Scientific Corporation | $3,236 | Research payment | Cash or cash equivalent | CLINICAL TRIAL PRODUCT Device, CLINICAL TRIAL PRODUCT | AGENT IDE | 2022 |
| 2022-12-19 | Amryt Pharma Holdings Ltd | $1,361 | Research payment | Cash or cash equivalent | MYCAPSSA Drug, Endocrinology | MACRO Registry | 2022 |
| 2022-12-19 | Boston Scientific Corporation | $1,300 | Research payment | Cash or cash equivalent | CLINICAL TRIAL PRODUCT Device, CLINICAL TRIAL PRODUCT | AGENT IDE | 2022 |
| 2022-12-19 | PFIZER INC. | $682 | Research payment | In-kind items and services | BRAFTOVI Drug, ONCOLOGY | AN OPENLABEL MULTICENTER RANDOMIZED PHASE 3 STUDY OF FIRSTLINE ENCORAFENIB PLUS CETUXIMAB WITH OR WITHOUT CHEMOTHERAPY V | 2022 |
| 2022-12-19 | Boston Scientific Corporation | $455 | Research payment | Cash or cash equivalent | CLINICAL TRIAL PRODUCT Device, CLINICAL TRIAL PRODUCT | AGENT IDE | 2022 |
| 2022-12-18 | PROGENICS PHARMACEUTICALS, INC. | $2,500 | Long term medical supply or device loan | In-kind items and services | PYLARIFY AI Device, Radiology DICOM Image Processing Application Software | 2022 | |
| 2022-12-16 | Paragon 28, Inc. | $11,450 | Research payment | Cash or cash equivalent | Phantom Hindfoot TTC/TC Nail System Device, Foot and Ankle Implants | Phantom Hindfoot TTC/TC Nail System Post-Market Clinical Follow-Up Study | 2022 |
| 2022-12-16 | Genentech, Inc. | $10,371 | Research payment | Cash or cash equivalent | Drug | A PHASE 2B EFFICACY SAFETY TRIAL OF PRASINEZUMAB IN PATIENTS WITH EARLY PARKINSON S DISEASE | 2022 |
| 2022-12-16 | Takeda Pharmaceuticals U.S.A., Inc. | $3,000 | Space rental or facility fees (teaching hospital only) | Cash or cash equivalent | 2022 | ||
| 2022-12-15 | Roche Diagnostics Operations, Inc. | $250,000 | Research payment | Cash or cash equivalent | Device | RD006395 | 2022 |
| 2022-12-15 | Abbott Laboratories | $11,400 | Research payment | Cash or cash equivalent | Device, Structural Heart | Clinical Trial to Evaluate the Safety and Effectiveness of Using the Tendyne Mitral Valve System for the Treatment of Sy | 2022 |
| 2022-12-15 | Abbott Laboratories | $10,600 | Research payment | Cash or cash equivalent | Device, Structural Heart | Clinical Trial to Evaluate the Safety and Effectiveness of Using the Tendyne Mitral Valve System for the Treatment of Sy | 2022 |
| 2022-12-15 | E.R. Squibb & Sons, L.L.C. | $2,000 | Space rental or facility fees (teaching hospital only) | Cash or cash equivalent | ELIQUIS Drug, Cardiovascular | 2022 | |
| 2022-12-15 | Eli Lilly and Company | $706 | Research payment | In-kind items and services | AN OPEN-LABEL, STUDY TO EVALUATE THE SAFETY AND EFFICACY OF LEBRIKIZUMAB IN ADULT AND ADOLESCENT PARTICIPANTS WITH MODER | 2022 | |
| 2022-12-15 | Eli Lilly and Company | $585 | Research payment | In-kind items and services | AN OPEN-LABEL, 24-WEEK STUDY TO INVESTIGATE THE SAFETY AND EFFICACY OF LEBRIKIZUMAB IN ADULT AND ADOLESCENT PARTICIPANTS | 2022 | |
| 2022-12-14 | Arthrex, Inc. | $14,300 | Research payment | Cash or cash equivalent | SHOULDER SUTURE FIBERWIRE #2 FIBERWIRE Device, SHOULDER - SUTURE - FIBERWIRE - #2 FIBERWIRE | IIRR-01098_Biomechanical Evaluation of Posterolateral Corner Reconstruction with_IIBM/100 | 2022 |
| 2022-12-14 | Intercept Pharmaceuticals, Inc. | $1,872 | Research payment | Cash or cash equivalent | OCALIVA Drug, Hepatology / Gastroenterology | Randomized Global Phase 3 Study to Evaluate the Impact on NASH With Fibrosis of Obeticholic Acid Treatment (REGENERATE) | 2022 |
| 2022-12-13 | MorphoSys AG | $34,650 | Research payment | Cash or cash equivalent | MONJUVI Drug, Oncology | A phase 3, multicenter, randomized, double-blind, placebo-controlled trial comparing the efficacy and safety of tafasita | 2022 |
| 2022-12-13 | Travere Therapeutics, Inc. | $2,002 | Research payment | Cash or cash equivalent | 021FSGS16010 | 2022 | |
| 2022-12-13 | Travere Therapeutics, Inc. | $2,002 | Research payment | Cash or cash equivalent | 021FSGS16010 | 2022 | |
| 2022-12-12 | Edwards Lifesciences Corporation | $33,879 | Research payment | Cash or cash equivalent | THE ENCIRCLE Trial (#2018-19) | 2022 | |
| 2022-12-12 | Janssen Research & Development, LLC | $6,943 | Research payment | Cash or cash equivalent | An Open label Phase 11b Study to Evaluate the Safety and Pharmacokinetics of JNJ73841937 Lazertinib a Third Generation E | 2022 | |
| 2022-12-12 | E.R. Squibb & Sons, L.L.C. | $50 | Research payment | Cash or cash equivalent | OPDIVO Biological, Oncology | Phase III Adjuvant Melanoma Monotherapy | 2022 |
| 2022-12-11 | Applied Medical Resources Corporation | $18,500 | Research payment | Cash or cash equivalent | Voyant electrosurgical generator Device, VOYANT SYSTEMS | Applied Medical Voyant | 2022 |
| 2022-12-11 | Abbott Laboratories | $349 | Space rental or facility fees (teaching hospital only) | Cash or cash equivalent | 2022 | ||
| 2022-12-09 | Janssen Research & Development, LLC | $14,183 | Research payment | Cash or cash equivalent | ERLEADA Drug, Oncology | A Randomized Double blind Placebo controlled Phase 3 Study of Apalutamide in Subjects with High risk Localized or Locall | 2022 |
| 2022-12-09 | Janssen Research & Development, LLC | $14,183 | Research payment | Cash or cash equivalent | ERLEADA Drug, Oncology | A Randomized Double blind Placebo controlled Phase 3 Study of Apalutamide in Subjects with High risk Localized or Locall | 2022 |
The latest 200 records of 1,283.
CMS Open Payments: payments and transfers of value that drug and medical device makers and group purchasing organizations report to Medicare, program years 2019 on, as published by CMS (general, research and ownership records; refreshed by CMS each June and January). Links to other records on this site are by name (and state) only.
The area Census
County outline, the place (blue), the tract (orange) and the ZIP center (dot).
In West Hollywood, CA, county Los Angeles County, CA, state California; placed by its city name.
| Measure | Place (city or town) West Hollywood, CA | County Los Angeles County, CA | State California |
|---|---|---|---|
| Population B01003 | 34,884 | 9,808,667 | 39,287,377 |
| Population, 2020 census P1 | 35,757 | 10,014,009 | 39,538,223 |
| Median age B01002 | 40.0 | 38.2 | 37.9 |
| Under 18 B01001 | 3.6% | 20.6% | 22.0% |
| 65 and over B01001 | 16.8% | 15.2% | 15.7% |
| Households B11001 | 22,920 | 3,416,449 | 13,548,091 |
| Foreign born B05002 | 23.6% | 33.4% | 27.0% |
| Median household income B19013 | $96,995 | $90,112 | $99,122 |
| Median family income B19113 | $126,364 | $101,573 | $113,346 |
| Per capita income B19301 | $90,080 | $45,792 | $49,513 |
| Poverty rate B17001 | 12.9% | 13.7% | 12.0% |
| Unemployment rate B23025 | 8.9% | 7.3% | 6.6% |
| Civilian labor force B23025 | 25,818 | 5,200,656 | 20,068,466 |
| Mean commute (minutes) B08013 | 27.1 | 30.4 | 28.7 |
| Bachelor's degree or higher B15003 | 64.2% | 36.0% | 37.1% |
| Housing units B25001 | 26,079 | 3,650,466 | 14,644,735 |
| Owner-occupied B25003 | 19.8% | 45.9% | 55.9% |
| Renters B25003 | 80.2% | 54.1% | 44.1% |
| Median home value B25077 | $924,800 | $834,200 | $734,700 |
| Median gross rent B25064 | $2,091 | $1,954 | $2,036 |
| White, not Hispanic B03002 | 69.5% | 24.7% | 33.8% |
| Black B03002 | 4.3% | 7.4% | 5.2% |
| Hispanic or Latino B03002 | 13.1% | 48.4% | 40.2% |
| Asian B03002 | 6.1% | 14.9% | 15.3% |
| American Indian and Alaska Native B03002 | 0.1% | 0.2% | 0.3% |
Economy now FRED unemployment 5.1% in Sep 2026 (5.5% a year earlier); per capita personal income $90,957 in 2025, up 30% in five years (+4.3% after inflation); the state; Source: FRED, Federal Reserve Bank of St. Louis.
Data: IPUMS NHGIS (ACS 2020-2024 and the 2020 census); each figure links to its table for that area at data.census.gov. Records are placed by ZIP code and city name, not street address. More: everything FURP has in West Hollywood, CA.
Comments